|
Can-Fite on go with mid-stage study of namodenoson in fatty liver disease - Seeking Alpha
<img alt="" height="1" width="1"> Can-Fite on go with mid-stage study of namodenoson in fatty liver disease Seeking Alpha The primary endpoint will be the percent change from baseline in liver triglyceride concentration as measured by nuclear magnetic resonance spectroscopy. Namodenoson, formerly CF102, is an orally available small molecule that binds to a protein that is ... Can-Fite BioPharma (CANF) Says Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient ...StreetInsider.com all 4 news articles » Can-Fite on go with mid-stage study of namodenoson in fatty liver disease - Seeking Alpha More... |
| All times are GMT. The time now is 06:19 AM. |
Powered by vBulletin® Version 3.7.3
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Search Engine Friendly URLs by vBSEO 3.6.0
Copyright, BioNMR.com, 2003-2013